http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2018002510-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_566851fdc856afb339e3f24f03896ce4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
filingDate 2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea70e44f082889c46e302c1983d3e1c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac44194663cfedbab00ae5dd3dddc75d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d853d9c93cb40026217d5bc2f5f4999d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_826f484be4957995c13f1a4300905b0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3be234485cdd8d58681ae4a6c0bb8a88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26b852748fa5d01d00a8b8c2ea4e8bce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c2e59a05742f55861b30c916bee5e58
publicationDate 2018-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2018002510-A
titleOfInvention PHARMACEUTICAL COMBINATION FOR DISORDERS OF THE STATE OF ANIMO.
abstract The present invention relates to a pharmaceutical composition comprising the synergistic combination of an NMDA receptor antagonist agent, such as the active ingredient: ketamine and an MT1 and MT2 melatonin receptor agonist agent, such as the active ingredient: Melatonin, which are in a pharmaceutical composition, which is indicated for the control and treatment of psychiatric diseases.
priorityDate 2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID896
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3821
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507128
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492924

Total number of triples: 35.